To establish the BC Cancer Agency - Vancouver Centre as a major SWOG centre

Blanke, Charles D.

Abstract

The purpose of this application is to request a grant to support the BC Cancer Agency - Vancouver in becoming a major SWOG centre. The application provides justification and information to support our grant application.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Cooperative Clinical Research--Cooperative Agreements (U10)
• Project #: 5U10CA142559-02
• Application #: 8053417
• Study Section: Subcommittee G - Education (NCI)
• Program Officer: Mooney, Margaret M
• Project Start: 2010-03-30
• Project End: 2012-12-31
• Budget Start: 2011-01-10
• Budget End: 2011-12-31
• Support Year: 2
• Fiscal Year: 2011
• Total Cost: $188,304

Institution

• Name: British Columbia Cancer Agency
• DUNS #: 209137736
• City: Vancouver
• State: BC
• Country: Canada
• Zip Code: V5 1-L3

Publications

Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127

Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7

Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8

Mahadevan, Daruka; Unger, Joseph M; Spier, Catherine M et al. (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119:371-9